|
|
|

|
|
- Continued Shortage of
Haemophilus influenzae
Type b (Hib) Conjugate Vaccines and
Potential Implications for Hib Surveillance ---
United States, 2008.
MMWR Nov 21 2008:57(46);1252-5. [Dec 08]
- no increase
in disease due to shortage
- IVS has learned that no samples
of the recalled lots were found to be contaminated.
[Dec 08]
-
Pentacel, a vaccine for active immunization
against diphtheria, tetanus, pertussis,
poliomyelitis and invasive disease caused by
Haemophilus influenzae type b for infants and
children 6 weeks through 4 years of age (prior to
fifth birthday), was approved by the US FDA in June
2008.
- Ten lots of
PedvaxHIB and two lots of
COMVAX are being
voluntarily recalled by Merck and Co due to concerns
about product sterility. The recall involves
approximately 1 million doses of vaccine. The
risk of vaccine contamination is reportedly
theoretical; no vaccines have been found to be
contaminated and there have been no reports of
illness or injury. (Dec 07)
• The FDA
has listed the specific lots that are being recalled
at:
www.fda.gov/cber/recalls/merckhib121107.htm
• CDC Q&A regarding the
recall:
http://www.cdc.gov/vaccines/recs/recalls/hib-recall-faqs-12-12-07.htm
• Merck's National Service
Center that can answer questions about medical and
other issues related to this recall: 1-800-672-6372
•
Letter from Merck with more information:
http://www.cdc.gov/vaccines/vac-gen/shortages/downloads/hib-recall-12-12-07.doc
|
|

This page
was last updated on
June 11, 2009
© 2007
Institute for Vaccine Safety |
|